Refine
Year of publication
Document Type
- Article (142)
- Preprint (36)
- Report (2)
- Review (2)
- Conference Proceeding (1)
- Working Paper (1)
Has Fulltext
- yes (184)
Is part of the Bibliography
- no (184)
Keywords
- LHC (7)
- Breast cancer (4)
- breast cancer (4)
- ALICE (3)
- ALICE experiment (3)
- Depression (3)
- Hadron-Hadron Scattering (3)
- pp collisions (3)
- Beauty production (2)
- Bipolar disorder (2)
- COVID-19 (2)
- Diagnostik (2)
- Früherkennung (2)
- Gene expression (2)
- HNSCC (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Richtlinie (2)
- SARS-CoV-2 (2)
- Single electrons (2)
- Surgery (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 18-Hydroxycorticosteron (1)
- 18-OH corticosterone (1)
- 900 GeV (1)
- AChE (1)
- APP (1)
- Active middle ear implants (1)
- Adherencia terapéutica (1)
- Afghanistan (1)
- Alzheimer (1)
- Amizon (1)
- Amyloid precursor protein (1)
- Anandamide (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antirheumatic agents (1)
- Arteria ophthalmica (1)
- Artificial Intelligence (1)
- Atoms (1)
- Auditory system (1)
- Behavior (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Blindness (1)
- Bone conduction devices (1)
- Bone metastases (1)
- Botanical Collections (1)
- Business strategy in drug development (1)
- C3M (1)
- C4M (1)
- CA1 (1)
- CCL2 (1)
- CRISPR/Cas (1)
- CVID (1)
- Cell membranes (1)
- Charm physics (1)
- Chemical dispersant (1)
- Child (1)
- Child abuse (1)
- Childhood abuse (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Clinical variation (1)
- Cognitive impairment (1)
- Compact astrophysical objects (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex posttraumatic stress disorder (1)
- Compression stocking (1)
- Consensus (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biogeography (1)
- DBT (1)
- DBT-PTS (1)
- DBT-PTSD (1)
- DBTTSD (1)
- Dataset bias (1)
- Ddialectic behavioural therapy (1)
- Deep vein thrombosis (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Dialectical behavioural therapy (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Digitization (1)
- Drug therapy (1)
- Dtherapeutic adherencetreatment integrity (1)
- EROD (1)
- Elderly (1)
- Embryo toxicity (1)
- Endocrinology (1)
- Epilepsy (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Excitability (1)
- Exilliteratur (1)
- Exilschriftsteller (1)
- Exilverlag (1)
- Exosomes (1)
- Extended donor criteria (1)
- FAV00A (1)
- FDG-PET/CT (1)
- FDM (1)
- Femtoscopy (1)
- Filler (1)
- Forschungsdatenmanagement (1)
- Frailty (1)
- Freiligrath, Ferdinand (1)
- Galaxies and clusters (1)
- General practitioners (1)
- Genetic wildlife monitoring (1)
- Genetics (1)
- Genome editing (1)
- German PID-NET registry (1)
- Glabella (1)
- Global positioning system (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HDAC4 (1)
- HER2-positive (1)
- HPV-positive OPSCC (1)
- Hadron production (1)
- Hair sampling (1)
- Head and neck cancer (1)
- Head neck cancer (1)
- Health policy (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Heinzen, Karl (1)
- Herbaria (1)
- High-energy astrophysics (1)
- Human behaviour (1)
- Hypertension (1)
- IN-VIVO (1)
- IS (1)
- IgG substitution therapy (1)
- Immunology (1)
- Immunotherapy (1)
- In situ burning (1)
- Inclusive spectra (1)
- Induction therapy (1)
- Inflammation (1)
- Integridad del tratamiento (1)
- Intensity interferometry (1)
- Intravenous injections (1)
- Ions (1)
- Irak (1)
- Islamischer Staat (1)
- Jets (1)
- Kidney diseases (1)
- Knockout (1)
- LOCKED NUCLEIC-ACID (1)
- Landesinitiative (1)
- Landesinitiative für Forschungsdatenmanagement (1)
- Lee-type (1)
- Library screening (1)
- Literarisches Institut (Herisau) (1)
- Luciferase (1)
- Lure sticks (1)
- Lymphoid Neoplasia (1)
- MAMMALIAN-CELLS (1)
- MODIFIED OLIGONUCLEOTIDES (1)
- Marker genes (1)
- Mental health and psychiatry (1)
- MicroRNAs (1)
- Microarray (1)
- Microglial cells (1)
- Mid-rapidity (1)
- Mixed hearing loss (1)
- Mott metal-insulator transition (1)
- Mouse models (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- NCoR1 (1)
- NFDI (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- Nationale Forschungsdateninfrastruktur (1)
- Nebennierenrinden-Adenom (1)
- Nebennierenrinden-Hyperplasie (1)
- Neoadjuvant therapy (1)
- Neuronal morphology (1)
- Neurons (1)
- Neuroscience (1)
- Noninvasive genetic sampling (1)
- Nuclear modification factor (1)
- Occlusion (1)
- Oldest-old (1)
- Oncology (1)
- Ophthalmoplegia (1)
- Optogenetics (1)
- Organ allocation (1)
- PASSENGER-STRAND (1)
- PID prevalence (1)
- PTS (1)
- PTSD (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parkinson disease (1)
- Pathological complete response (1)
- Patterns of care (1)
- Pb–Pb (1)
- Perturbative methods (1)
- Phosphorylation (1)
- Pooling (1)
- Population-based screening (1)
- Post-traumatic stress disorder (1)
- Posttraumatic stress disorder (1)
- Proton–proton (1)
- Psychological and psychosocial issues (1)
- Pulmonary embolism (1)
- Quality of life (1)
- RDM (1)
- RNA polymerase (1)
- RT-qPCR (1)
- Radiotherapy (1)
- Randomised controlled trial (1)
- Recall rate (1)
- Red blood cell transfusion (1)
- Referenzwechsel (1)
- Rehabilitation (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Research Data Management (1)
- Research Infrastructure (1)
- Retinal diseases (1)
- Revolution <1848> (1)
- Rhabdomyoma (1)
- SENP (1)
- SMALL INTERFERING RNA (1)
- STRUCTURAL BASIS (1)
- SUMO (1)
- Salivary gland carcinoma (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Schweiz (1)
- Seizure (1)
- Semantics (1)
- Single muons (1)
- Small molecules (1)
- Spine density (1)
- Sprachtypologie (1)
- Swimming behavior (1)
- Synaptic plasticity (1)
- Syrien (1)
- TEPT (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- Taliban (1)
- Taxonomy (1)
- Technical data (1)
- Terapia Dialéctica Conductual (1)
- Tetrahydro-Aldosteron (1)
- Therapeutics (1)
- Transverse momentum (1)
- Trastorno de estrés postraumático (1)
- Triple negative (1)
- Type 2 diabetes (1)
- Venous thromboembolism (1)
- Vesicles (1)
- Yellow fluorescent protein (1)
- adrenal adenomas (1)
- anaemia (1)
- anterior chamber depth changes (1)
- antibiotic therapy (1)
- antibodies (1)
- apex (1)
- ascites (1)
- autoantibodies (1)
- b-cell lymphomas (1)
- bendamustine (1)
- biopsy (1)
- cardiac I/R injury (1)
- cataract surgery (1)
- cetuximab (1)
- charge-cluster glass (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- collagen degradation marker (1)
- combined modality therapy (1)
- dentate gyrus (1)
- diabetic macular edema (1)
- dislocation (1)
- double immune checkpoint inhibition (1)
- e-scooter (1)
- effective lens position (1)
- elderly patients (1)
- electric scooter (1)
- fear conditioning (1)
- fluctuation spectroscopy (1)
- fluocinolone acetonide (1)
- fracture (1)
- functional outcome (1)
- glass-like structural ordering (1)
- head and neck neoplasms (1)
- hematopoietic stem cell transplantation (1)
- imaging (1)
- immunoprecipitation (1)
- immunostaining (1)
- immunotherapy (1)
- in situ hybridization (1)
- induction therapy (1)
- lapatinib (1)
- laser microdissection (1)
- learning (1)
- leukapheresis (1)
- liver cirrhosis (1)
- lymphoma (1)
- mTOR inhibitor (1)
- mass spectrometry (1)
- medial prefrontal cortex (mPFC) (1)
- membranous urethra (1)
- memory consolidation and extinction (1)
- microdosing (1)
- mid-term urinary continence (1)
- molecular dynamics simulation (1)
- multidrug resistance (1)
- neoadjuvant therapy (1)
- neutralizing antibodies (1)
- organ preservation (1)
- organic charge-transfer salts (1)
- papilloma (1)
- percolation (1)
- primary aldosteronism (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (PID) (1)
- primärer Hyperaldosteronismus (1)
- prostate cancer (1)
- proteomics (1)
- pseudoexfoliative syndrome (1)
- radical prostatectomy (1)
- re-irradiation (1)
- registry for primary immunodeficiency (1)
- rituximab (1)
- screening routine (1)
- second line therapy (1)
- spectra (1)
- spike protein (1)
- surgery (1)
- tetrahydroaldosterone (1)
- traffic accident (1)
- transcranial magnetic stimulation (TMS) (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- treatment response (1)
- ursodeoxycholic acid (1)
- variants of concern (1)
- western blotting (1)
- √sN N = 2.76 TeV (1)
- 创伤后应激障碍 (1)
- 治疗依从性 (1)
- 治疗完整性 (1)
- 辩证行为疗法 (1)
Institute
- Physik (83)
- Medizin (72)
- Frankfurt Institute for Advanced Studies (FIAS) (69)
- Informatik (68)
- Geowissenschaften (7)
- Biowissenschaften (5)
- Biochemie und Chemie (4)
- Psychologie (3)
- Senckenbergische Naturforschende Gesellschaft (3)
- ELEMENTS (2)
Introduction: Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are most useful in ER-positive cancers. Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat this disease.
Methods: We assembled Affymetrix gene expression data for 579 TNBC and performed unsupervised analysis to define metagenes that distinguish molecular subsets within TNBC. We used n = 394 cases for discovery and n = 185 cases for validation. Sixteen metagenes emerged that identified basal-like, apocrine and claudin-low molecular subtypes, or reflected various non-neoplastic cell populations, including immune cells, blood, adipocytes, stroma, angiogenesis and inflammation within the cancer. The expressions of these metagenes were correlated with survival and multivariate analysis was performed, including routine clinical and pathological variables.
Results: Seventy-three percent of TNBC displayed basal-like molecular subtype that correlated with high histological grade and younger age. Survival of basal-like TNBC was not different from non basal-like TNBC. High expression of immune cell metagenes was associated with good and high expression of inflammation and angiogenesis-related metagenes were associated with poor prognosis. A ratio of high B-cell and low IL-8 metagenes identified 32% of TNBC with good prognosis (hazard ratio (HR) 0.37, 95% CI 0.22 to 0.61; P < 0.001) and was the only significant predictor in multivariate analysis including routine clinicopathological variables.
Conclusions: We describe a ratio of high B-cell presence and low IL-8 activity as a powerful new prognostic marker for TNBC. Inhibition of the IL-8 pathway also represents an attractive novel therapeutic target for this disease.
Background: Current prognostic gene signatures for breast cancer mainly reflect proliferation status and have limited value in triple-negative (TNBC) cancers. The identification of prognostic signatures from TNBC cohorts was limited in the past due to small sample sizes.
Methodology/Principal Findings: We assembled all currently publically available TNBC gene expression datasets generated on Affymetrix gene chips. Inter-laboratory variation was minimized by filtering methods for both samples and genes. Supervised analysis was performed to identify prognostic signatures from 394 cases which were subsequently tested on an independent validation cohort (n = 261 cases).
Conclusions/Significance: Using two distinct false discovery rate thresholds, 25% and <3.5%, a larger (n = 264 probesets) and a smaller (n = 26 probesets) prognostic gene sets were identified and used as prognostic predictors. Most of these genes were positively associated with poor prognosis and correlated to metagenes for inflammation and angiogenesis. No correlation to other previously published prognostic signatures (recurrence score, genomic grade index, 70-gene signature, wound response signature, 7-gene immune response module, stroma derived prognostic predictor, and a medullary like signature) was observed. In multivariate analyses in the validation cohort the two signatures showed hazard ratios of 4.03 (95% confidence interval [CI] 1.71–9.48; P = 0.001) and 4.08 (95% CI 1.79–9.28; P = 0.001), respectively. The 10-year event-free survival was 70% for the good risk and 20% for the high risk group. The 26-gene signatures had modest predictive value (AUC = 0.588) to predict response to neoadjuvant chemotherapy, however, the combination of a B-cell metagene with the prognostic signatures increased its response predictive value. We identified a 264-gene prognostic signature for TNBC which is unrelated to previously known prognostic signatures.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Since the introduction of rental E-scooters in Germany in mid-June 2019, the safety of this new means of transport has been the subject of extensive public debate. However, valid data on injuries and usage habits are not yet available. This retrospective two-center study included a total of 76 patients who presented to the emergency department following E-scooter-related accidents. The mean age was 34.3 ± 12.4 years and 69.7% of the patients were male. About half of the patients were admitted by ambulance (42.1%). Fractures were found in 48.6% of patients, and 27.6% required surgical treatment due to a fracture. The upper extremities were the most commonly affected body region, followed by injuries to the lower extremity and to the head and face. Only one patient had worn a helmet. In-hospital treatment was necessary for 26.3% of the cases. Patients presented to the emergency department mainly during the weekend and on-call times. This is the first report on E-scooter-related injuries in Germany. Accidents with E-scooters can cause serious injuries and, therefore, represent a further burden to emergency departments. The use of E-scooters appears to be mostly recreational, and the rate of use of protective gear is low.
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML.
TRIAL DESIGN: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.
PATIENTS AND METHODS: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/µl at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint.
RESULTS: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days.
CONCLUSIONS: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm.
DGK and DZHK position paper on genome editing: basic science applications and future perspective
(2021)
For a long time, gene editing had been a scientific concept, which was limited to a few applications. With recent developments, following the discovery of TALEN zinc-finger endonucleases and in particular the CRISPR/Cas system, gene editing has become a technique applicable in most laboratories. The current gain- and loss-of function models in basic science are revolutionary as they allow unbiased screens of unprecedented depth and complexity and rapid development of transgenic animals. Modifications of CRISPR/Cas have been developed to precisely interrogate epigenetic regulation or to visualize DNA complexes. Moreover, gene editing as a clinical treatment option is rapidly developing with first trials on the way. This article reviews the most recent progress in the field, covering expert opinions gathered during joint conferences on genome editing of the German Cardiac Society (DGK) and the German Center for Cardiovascular Research (DZHK). Particularly focusing on the translational aspect and the combination of cellular and animal applications, the authors aim to provide direction for the development of the field and the most frequent applications with their problems.
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and a major cause of morbidity among children with pediatric rheumatic diseases. The management of JDM is very heterogeneous. The JDM working group of the Society for Pediatric Rheumatology (GKJR) aims to define consensus- and practice-based strategies in order to harmonize diagnosis, treatment and monitoring of JDM.
Methods: The JDM working group was established in 2015 consisting of 23 pediatric rheumatologists, pediatric neurologists and dermatologists with expertise in the management of JDM. Current practice patterns of management in JDM had previously been identified via an online survey among pediatric rheumatologists and neurologists. Using a consensus process consisting of online surveys and a face-to-face consensus conference statements were defined regarding the diagnosis, treatment and monitoring of JDM. During the conference consensus was achieved via nominal group technique. Voting took place using an electronic audience response system, and at least 80% consensus was required for individual statements.
Results: Overall 10 individual statements were developed, finally reaching a consensus of 92 to 100% regarding (1) establishing a diagnosis, (2) case definitions for the application of the strategies (moderate and severe JDM), (3) initial diagnostic testing, (4) monitoring and documentation, (5) treatment targets within the context of a treat-to-target strategy, (6) supportive therapies, (7) explicit definition of a treat-to-target strategy, (8) various glucocorticoid regimens, including intermittent intravenous methylprednisolone pulse and high-dose oral glucocorticoid therapies with tapering, (9) initial glucocorticoid-sparing therapy and (10) management of refractory disease.
Conclusion: Using a consensus process among JDM experts, statements regarding the management of JDM were defined. These statements and the strategies aid in the management of patients with moderate and severe JDM.
Background: Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGIF is associated with BC bone metastasis or patient outcome and thus of potential interest. Methods: TGIF expression was analyzed by immunohistochemistry in 1197 formalin-fixed, paraffin-embedded tissue samples from BC patients treated in the GAIN (German Adjuvant Intergroup Node-Positive) study with two adjuvant dose-dense schedules of chemotherapy with or without bisphosphonate ibandronate. TGIF expression was categorized into negative/low and moderate/strong staining. Endpoints were disease-free survival (DFS), overall survival (OS) and time to primary bone metastasis as first site of relapse (TTPBM). Results: We found associations of higher TGIF protein expression with smaller tumor size (p= 0.015), well differentiated phenotype (p< 0.001) and estrogen receptor (ER)-positive BC (p< 0.001). Patients with higher TGIF expression levels showed a significantly longer disease-free (DFS: HR 0.75 [95%CI 0.59–0.95], log-rank p=0.019) and overall survival (OS: HR 0.69 [95%CI 0.50–0.94], log-rank p= 0.019), but no association with TTPBM (HR 0.77 [95%CI 0.51–1.16]; p= 0.213). Univariate analysis in molecular subgroups emphasized that elevated TGIF expression was prognostic for both DFS and OS in ER-positive BC patients (DFS: HR 0.68 [95%CI 0.51–0.91]; log-rank p= 0.009, interaction p= 0.130; OS: HR 0.60 [95%CI 0.41–0.88], log-rank p= 0.008, interaction p= 0.107) and in the HER2-negative subgroup (DFS:HR 0.67 [95%CI 0.50–0.88], log-rank p= 0.004, interaction p= 0.034; OS: HR 0.57 [95%CI 0.40–0.81], log-rank p= 0.002, interaction p= 0.015). Conclusions: Our results suggest that moderate to high TGIF expression is a common feature of breast cancer cells and that this is not associated with bone metastases as first site of relapse. However, a reduced expression is linked to tumor progression, especially in HER2-negative breast cancer.
Following publication of the original article, the authors noticed an incorrect affiliation for Christine Stürken and Udo Schumacher. The correct affiliations are as follows: Christine Stürken: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Udo Schumacher: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. The affiliations have been correctly published in this correction and the original article has been updated.
We have sampled atmospheric ice nuclei (IN) and aerosol in Germany and in Israel during spring 2010. IN were analyzed by the static vapor diffusion chamber FRIDGE, as well as by electron microscopy. During the Eyjafjallajökull volcanic eruption of April 2010 we have measured the highest ice nucleus number concentrations (>600 l−1) in our record of 2 yr of daily IN measurements in central Germany. Even in Israel, located about 5000 km away from Iceland, IN were as high as otherwise only during desert dust storms. The fraction of aerosol activated as ice nuclei at −18 °C and 119% rhice and the corresponding area density of ice-active sites per aerosol surface were considerably higher than what we observed during an intense outbreak of Saharan dust over Europe in May 2008.
Pure volcanic ash accounts for at least 53–68% of the 239 individual ice nucleating particles that we collected in aerosol samples from the event and analyzed by electron microscopy. Volcanic ash samples that had been collected close to the eruption site were aerosolized in the laboratory and measured by FRIDGE. Our analysis confirms the relatively poor ice nucleating efficiency (at −18 °C and 119% ice-saturation) of such "fresh" volcanic ash, as it had recently been found by other workers. We find that both the fraction of the aerosol that is active as ice nuclei as well as the density of ice-active sites on the aerosol surface are three orders of magnitude larger in the samples collected from ambient air during the volcanic peaks than in the aerosolized samples from the ash collected close to the eruption site. From this we conclude that the ice-nucleating properties of volcanic ash may be altered substantially by aging and processing during long-range transport in the atmosphere, and that global volcanism deserves further attention as a potential source of atmospheric ice nuclei.